Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
about
Interventions for preventing the progression of autosomal dominant polycystic kidney diseaseCurrent management of autosomal dominant polycystic kidney diseaseThe importance of total kidney volume in evaluating progression of polycystic kidney diseaseAutosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.Heterotrimeric G protein signaling in polycystic kidney diseaseHepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.Pharmacological management of polycystic kidney disease.Novel therapeutic approaches to autosomal dominant polycystic kidney disease.New options in the treatment of autosomal dominant polycystic kidney disease.Urinary Renin-Angiotensin Markers in Polycystic Kidney Disease.Clinical Trials and a View Toward the Future of ADPKD.Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context.Validation of Effective Therapeutic Targets for ADPKD Using Animal Models.Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease.Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease.The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease.Neonatal renal cystic diseases.New treatment paradigms for ADPKD: moving towards precision medicine.Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.Drug holiday in patients with polycystic liver disease treated with somatostatin analogues
P2860
Q24186484-92550D4E-1986-495E-A29B-FDBA2C612CBBQ26784073-A3F1198C-6A89-4E8C-A39F-750416C37DE8Q33873107-B4ABEA8D-23BC-497F-AC25-9B999FCB5906Q34467747-9C8765F2-F33A-4417-9622-980992A39E0DQ37139683-3B726BEB-358E-447E-B6B4-B4099C7FB006Q37620079-056CE681-217E-482E-91C5-1AEBD6FB3C67Q38199755-413503C8-B0AF-4F30-8335-4C85DAA8C59DQ38273327-9436AD79-01A1-4B2E-810E-72776D3E1D34Q38356125-2D682FB5-E3DD-4018-A505-B3E7DBCD23F8Q38651399-F620C312-85FA-41F0-825F-F2E3A45CC01CQ38812543-1FDF28C7-BDBA-428A-B366-E1A953AA60ABQ38919283-CD20FA85-C18D-43CF-8CCF-944A620E0BE4Q38978468-03022B9E-DC40-4A83-B5A5-E9BFBD82D5B2Q39199053-01DCCD2C-A8B2-410E-8859-6A45282795C1Q39884248-9E1E4B38-2BF2-410D-B05C-6446587FC565Q41645528-EDBA3237-970B-48C7-8643-FD993B92B86AQ47648297-D324CDC4-FE17-42EF-B26A-7D296E173133Q47651330-AF473AE5-7B19-4410-9D80-E96046BE4833Q48310990-1F54D198-8D2F-44A3-BB45-10FFD5DB986AQ49494721-CB19E135-7E77-433C-880A-4B02EFDA517DQ54367200-EC79CFBB-0BB1-4674-9153-AED9F0478840Q57298238-02B962BE-3327-4D7A-ADA8-812CA5E172A1
P2860
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Rationale and design of the DI ...... ant polycystic kidney disease.
@ast
Rationale and design of the DI ...... ant polycystic kidney disease.
@en
type
label
Rationale and design of the DI ...... ant polycystic kidney disease.
@ast
Rationale and design of the DI ...... ant polycystic kidney disease.
@en
prefLabel
Rationale and design of the DI ...... ant polycystic kidney disease.
@ast
Rationale and design of the DI ...... ant polycystic kidney disease.
@en
P2093
P2860
P1476
Rationale and design of the DI ...... ant polycystic kidney disease.
@en
P2093
DIPAK Consortium
Darius Soonawala
Dorien J M Peters
Edwin M Spithoven
Esther Meijer
Folkert W Visser
Hedwig d'Agnolo
Jack F M Wetzels
Johan W de Fijter
Joost P H Drenth
P2860
P304
P356
10.1053/J.AJKD.2013.10.011
P577
2013-12-15T00:00:00Z